Session information

Evening Seminar

[ES02] Evening Seminar 2　Incorporating checkpoint inhibitors into standard of care in advanced/metastatic gastric/GEJ cancer

Thu. Feb 17, 2022 7:00 PM - 7:50 PM Room 2 and 3 (Annex 1 and 2, 1F, Kyoto International Conference Center)

Chair：Kensei Yamaguchi（Gastroenterological Chemotherapy, Clinical Trial Planning and Management, Cancer Institute Hospital of Japanese Foundation for Cancer Research）

Sponsored by Bristol-Myers Squibb K.K. / ONO PHARMACEUTICAL CO., LTD.

[ES02-1] Incorporating checkpoint inhibitors into standard of care in advanced/metastatic gastric/GEJ cancer

^○Markus Moehler (Research Center for Immunotherapy (FZI), First Department of Internal Medicine, Johannes Gutenberg-University Clinic, Mainz, Germany)

▲

Session information

[ES02] Evening Seminar 2 Incorporating checkpoint inhibitors into standard of care in advanced/metastatic gastric/GEJ cancer

[ES02-1] Incorporating checkpoint inhibitors into standard of care in advanced/metastatic gastric/GEJ cancer

[ES02] Evening Seminar 2　Incorporating checkpoint inhibitors into standard of care in advanced/metastatic gastric/GEJ cancer